615. Evaluation of Durable Response Rate in the Post-Resection Setting and Association with Survival in Patients with Recurrent High Grade Glioma who Received Vocimagene Amiretroprepvec and 5-Fluorocytosine Treatment
Back to course
Asset Caption
Bob S. Carter, MD, PhD, FAANS, Assessment of the Trial Design/Level of Evidence - Frederick G. Barker II, MD, FAANS, Discussant - James M. Markert Jr., MD, FAANS